Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned a consensus recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $74.86.

Several brokerages have issued reports on JSPR. HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Evercore ISI reissued an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada dropped their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Finally, JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th.

Institutional Trading of Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter worth about $59,000. Fernwood Investment Management LLC boosted its stake in shares of Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after acquiring an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares during the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $20.43 on Tuesday. The firm has a 50 day simple moving average of $20.25 and a 200 day simple moving average of $20.94. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The company has a market cap of $308.60 million, a PE ratio of -4.31 and a beta of 2.19.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.